11/4/2026

speaker
Conference Call Operator
Operator

Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2026 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that this conference call is being recorded. GRAIL Investor Relations, please begin.

speaker
GRAIL Investor Relations
Investor Relations

Thank you, and thank you all for joining us today. On the call are Josh Ofman, our Chief Executive Officer, Aaron Freidin, Chief Financial Officer, Sir Harpal Kumar, Chief Scientific Officer and President, Global Clinical and Medical Affairs, and Andy Partridge, Chief Growth Officer. I'll remind you that we'll be making forward-looking statements based on current expectations. It's our intent that all statements, other than statements of historical fact, including statements regarding our anticipated financial results and commercial activity, will be covered by the safe harbor provisions for forward-looking statements under the federal securities laws. Forward-looking statements are subject to risk and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward-looking statements are based upon currently available information, and GRAIL assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the document that GRAIL files with the Securities and Exchange Commission, including the risk factors section in GRAIL's most recent annual report on Form 10-K, and the quarterly report on Form 10-Q we plan to file for the third quarter of 2026. This call will also include a discussion of GAAP results and certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, and adjusted EBITDA, which excludes certain specified items. Our non-GAAP financial measures are intended to supplement your understanding of Grail's financials. Reconciliations of the non-GAAP measures to most directly comparable GAAP financial measures are available in the press release issued today, which is available on our website. With that, we turn to Josh.

speaker
Josh Ofman
Chief Executive Officer

Thank you. Good afternoon, everyone, and thank you for joining us to review results for the third quarter of 2026 and to discuss recent business updates. GRAIL achieved multiple significant milestones this quarter, from the FDA's Advisory Committee, and the publication of NHS Gallery and Pathfinder 2 results in the New England Journal of Medicine and Nature Medicine. These important clinical and regulatory milestones position us very well as we continue to progress towards future potential regulatory approval and reimbursement. As you know, we submitted our pre-market approval application for Gallery to the FDA in January of this year. And on September 23rd, the FDA convened an expert advisory committee to consider the safety, effectiveness, and overall benefit-risk profile of Gallery for screening. for the early detection of multiple types of cancer in adults age 50 years and older. Gallery is the first multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were very pleased with the positive vote. The advisory committee discussion highlighted the high evidence bar that GRAIL has set for the entire field of multi-cancer detection tests. We're engaged in interactive communications with the FDA since the Advisory Committee, and we expect to receive a final decision by early Q1 of 2027. Galleries supported by a broad evidence base demonstrating its ability to detect cancer signals across over 140 cancer types and subtypes with a very low false positive rate and accurately identify cancer signal origin for those positive signals to support an efficient and directed workup. Based on what has now been demonstrated, we believe that adding gallery to recommended single cancer screens can dramatically improve the effectiveness and the efficiency of national screening programs around the globe. This is best exemplified by a clear finding from the NHS Gallery randomized controlled trial. When Gallery was added to standard of care, more than four times more cancers were identified overall, and Gallery found more stage one and two cancers than the entire UK's national screening program found all cancers across all stages. Now, this is remarkable and gives confidence that we can help improve how we screen for cancer and find cancers early before symptoms when there are opportunities for cure. We're very proud of our clinical evidence base, which we believe speaks for itself, and we continue to present and publish our studies in world-leading forums. In September, results from our two largest prospective studies, NHS Gallery and Pathfinder 2, were published in the New England Journal of Medicine and Nature Medicine. These publications build on the results we presented at ASCO earlier this year and demonstrate the many clinically meaningful benefits of Gallery. Across these studies, Gallery has detected over 140 distinct types and subtypes of cancer. We believe the results of the NHS Gallery trial demonstrated compelling clinical utility. Though we did not observe a combined reduction in stage 3 and 4 cancers, Gallery demonstrated the ability to generate a stage shift in cancer detection, producing a clinically meaningful reduction in stage 4 diagnoses. This is a historic achievement. Performance metrics such as PPV and safety in both the Pathfinder 2 and NHS Gallery study were strong and consistent across populations and studies. Together, these studies demonstrate the consistency of Gallery's performance across two very large screening populations and two unique healthcare systems. We believe the results provide strong evidence that adding gallery to standard of care screening can substantially increase the number of cancers identified through screening while maintaining a favorable safety profile. The clinical utility metric of overall cancer detection is compelling. A 4 to 6.5-fold increase in cancer detection through screening, almost half of which are early stage 1 and 2 cancers. and a 20% reduction in the incidence of stage 4 disease in a pre-specified group of 12 deadly cancers, a 25% reduction in the emergency room diagnosis of cancer, and of gallery-detected cancers at stage 1 through 3, more than 80% were treated with curative intent. As we await an FDA decision, we are focused on making investments that help us to clearly differentiate gallery and reduce much of the noise and confusion that exists in the marketplace. And we are also preparing for engagement with commercial payers and CMS. Turning to commercial performance in 2026, we continue to gain traction and see encouraging levels of volume growth. Test volumes increased 24% in Q3 as compared to the prior year, and to date, we have completed more than 174,000 tests in the first three quarters of the year, an increase of 36% from the prior year. In June, we expanded our provider sales force, and we continue to ramp new personnel for full productivity as we come out of the summer slowdown. We are also expanding access across provider, health system, employer, and digital channels through new and existing partnerships. We rolled out our first EPIC integration at the end of Q3, and we expect several more integrations through the end of the year. Now, Q3 has typically been a relatively slow quarter. and the effect was compounded this year by the impact in the marketplace related to negative headlines about the NHS Gallery results which continued during and after ASCO. Combined with a very active competitive marketplace, this tempered growth in Q3. We expect a potential Thank you for joining us. At this time, all MSEDs are lab-developed tests, but there is a perception that these tests are similar, but of course, they are far from the same. Comparing test performance from small case-controlled studies to large interventional studies in the screening population is simply not scientifically appropriate, and we believe that it is important for the benefits and harms to be understood through interventional studies in the screening population. On the heels of a positive FDA advisory committee and in anticipation of a potential FDA approval, we have started pulling forward our commercial investment, including the Salesforce expansion, launching our price promotion early, and increased investing in direct-to-consumer advertising. We expect to further increase investment in brand awareness and competitive differentiation going forward as we reshape the market. If we obtain FDA approval, we will clearly differentiate Gallery as a robust, well-validated, FDA-approved test. Overall, Grail has had a very busy quarter. We achieved an important regulatory milestone with the favorable FDA Advisory Committee vote. We strengthened Gallery's evidence base through publication of our two landmark clinical studies. and we continue to drive commercial penetration and build the foundation for broad market access. We are well positioned for continued growth as the clear leader in the MSED field and we are looking forward to a near-term FDA decision. We are preparing to drive growth acceleration if we receive approval. We believe this milestone will help support advancing engagements with health systems, self-insured employers, payers and guideline developers, as well as supporting greater conviction among providers and consumers. I'll now hand it over to Aaron for a review of our third quarter financials.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API